Lexaria Awarded Six Additional Patents

Core Viewpoint - Lexaria Bioscience Corp. has achieved a significant milestone by securing a total of 60 valid patents globally, enhancing its intellectual property portfolio and positioning itself for future commercial opportunities [1][9]. Patent Developments - The company has successfully obtained 6 new patents since its last update on October 9, 2025, indicating a proactive approach to intellectual property development [2]. - In Patent Family 20, Lexaria received its first patent in Australia for sublingual delivery of nicotine, complementing existing patents in the US, Canada, and Japan [3]. - The company has also secured its first European Union patent in Patent Family 21 for treating hypertension, which is significant given that Europe is the second-largest hypertension market globally [4]. - In Patent Family 24, Lexaria has strengthened its position with 2 new Australian patents and 1 new European Union patent for treating epilepsy, bringing the total to 6 US patents, 4 Australian patents, and 1 European Union patent [5]. - Additionally, in Patent Family 27, Lexaria has received 1 new US patent for treating diabetes, now holding 2 US patents in this family, which is crucial due to recent successes in the GLP-1 sector [6]. Research and Development - Lexaria's innovations are supported by a rigorous process that includes research, animal and human testing, and subsequent patent applications, allowing the company to pursue commercial relationships post-patent grants [7]. Shareholder Engagement - The company is reminding shareholders to vote in the upcoming Annual Meeting scheduled for January 27, 2026, emphasizing the importance of shareholder participation [8][10].